Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William G Goodman

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
The American Journal of Cardiology|July 23, 2015
Cardiovascular and Renal Outcomes Trials-Is There a Difference?Paolo Raggi, Robert Boer, William G Goodman, et al.
Pharmacoepidemiology and Drug Safety|July 8, 2011
The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover studyRyan D Kilpatrick, Mark D Danese, Vasily Belozeroff, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|December 21, 2021
Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomesJohn Mark Stephens, Kathleen M Fox, Pooja Desai, et al.
BMC Nephrology|April 19, 2013
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysisJaime L Natoli, Rob Boer, Brian H Nathanson, et al.
Pediatric Nephrology (Berlin, Germany)|April 25, 2003
Bone density measurements in pediatric patients with renal osteodystrophyEleonora M Lima, William G Goodman, Beatriz D Kuizon, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 3, 2012
Protocol adherence and the progression of cardiovascular calcification in the ADVANCE studyPablo A Ureña-Torres, Jürgen Floege, Carmel M Hawley, et al.
Journal of the American Society of Nephrology : JASN|June 10, 2005
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterolsIsidro B Salusky, William G Goodman, Shobha Sahney, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 29, 2011
Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterolsGlenn M Chertow, Z John Lu, Xiao Xu, et al.
Kidney International|October 23, 2014
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidismGeert J Behets, Goce Spasovski, Lulu R Sterling, et al.
Journal of the American Society of Nephrology : JASN|November 4, 2021
Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of HyperphosphatemiaWilliam G Goodman, Donald T Ward, Kevin J Martin, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
The American Journal of Cardiology|July 23, 2015
Cardiovascular and Renal Outcomes Trials-Is There a Difference?Paolo Raggi, Robert Boer, William G Goodman, et al.
Pharmacoepidemiology and Drug Safety|July 8, 2011
The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover studyRyan D Kilpatrick, Mark D Danese, Vasily Belozeroff, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|December 21, 2021
Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomesJohn Mark Stephens, Kathleen M Fox, Pooja Desai, et al.
BMC Nephrology|April 19, 2013
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysisJaime L Natoli, Rob Boer, Brian H Nathanson, et al.
Pediatric Nephrology (Berlin, Germany)|April 25, 2003
Bone density measurements in pediatric patients with renal osteodystrophyEleonora M Lima, William G Goodman, Beatriz D Kuizon, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 3, 2012
Protocol adherence and the progression of cardiovascular calcification in the ADVANCE studyPablo A Ureña-Torres, Jürgen Floege, Carmel M Hawley, et al.
Journal of the American Society of Nephrology : JASN|June 10, 2005
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterolsIsidro B Salusky, William G Goodman, Shobha Sahney, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 29, 2011
Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterolsGlenn M Chertow, Z John Lu, Xiao Xu, et al.
Kidney International|October 23, 2014
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidismGeert J Behets, Goce Spasovski, Lulu R Sterling, et al.
Journal of the American Society of Nephrology : JASN|November 4, 2021
Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of HyperphosphatemiaWilliam G Goodman, Donald T Ward, Kevin J Martin, et al.
Pageof 7